Aripiprazole as an Augmentation Agent in Treatment-Resistant Body Dysmorphic Disorder
Body dysmorphic disorder (BDD) is a relatively common and severe disorder for which pharmacotherapy has been only minimally studied. BDD often appears to respond to selective serotonin reuptake inhibitors (SSRIs), but many patients do not respond or respond only partially. Investigation of SSRI augmentation strategies is therefore needed. We report a case of treatment-resistant BDD that was successfully treated with pharmacological augmentation of fluvoxamine with aripiprazole. The patient, a 43-year-old woman, had been taking a stable dose of fluvoxamine (400 mg/day) for 6 months when she was started on aripiprazole (10 mg/day). After 10 weeks of this treatment, her clinical condition improved markedly, as indicated by a significant decrease in the Body Dysmorphic Disorder Examination score. This case presents some preliminary evidence that addition of the atypical antipsychotic agent aripiprazole may be useful in patients with treatment-resistant BDD. However, results from controlled studies are needed to support this finding.
KeywordsAripiprazole Fluvoxamine Pimozide Body Dysmorphic Disorder Augmentation Strategy
No sources of funding were used to assist in the preparation of this report. The authors have no conflicts of interest that are directly relevant to the content of this report.
- 1.American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, text revision, 2000Google Scholar
- 3.Phillips KA. The broken mirror: understanding and treating body dysmorphic disorder. New York: Oxford University Press, 1996: 162–4Google Scholar
- 4.Craven JL, Rodin GM.Cyproheptadine dependence associated with an atypical somatoform disorder? Can J Psychiatry 1987;32:143–5Google Scholar
- 7.Phillips KA. Treating body dysmorphic disorder using medication. Psychiatr Ann 2004; 34: 945–53Google Scholar
- 8.First MB, Spitzer RL, Williams JBW. Structured clinical interview for DSM-IV (SCID). Washington, DC: American Psychiatric Association, 1997Google Scholar
- 9.Corapcioglu A, Aydemir O, Yildiz M, et al. Structured clinical interview for DSM IV (SCID), Turkish version. Ankara: Hekimler Yayin Birligi, 1999Google Scholar
- 13.NCCMH, National Collaborating Centre for Mental Health. Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. London: British Psychiatric Society and Royal College of Psychiatrists, 2006Google Scholar
- 16.Sarkar R, Klein J, Krüger S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psycho-pharmacology 2008; 197: 687–8Google Scholar
- 18.Hadley S, Newcorn J, Hollander E. The neurobiology and psychopharmacology of body dysmorphic disorder. In: Castle D, Phillips K, editors. Disorders of body image. Petersfield: Wrightson Biomedical Publishing Ltd, 2002: 139–55Google Scholar